CoChat
Sign Up
Cited by 379Nanoparticle-Based Drug DeliveryAtherosclerosis and Cardiovascular DiseasesCardiac Imaging and Diagnostics

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Endothelial α ν β 3 Integrin–Targeted Fumagillin Nanoparticles Inhibit Angiogenesis in Atherosclerosis

Winter, Patrick M., Neubauer, Anne M., Caruthers, Shelton D., Harris, Thomas D., Robertson, J. David, Williams, Todd A., Schmieder, Anne H., Hu, Grace, Allen, John S., Lacy, Elizabeth K., Zhang, Huiying, Wickline, Samuel A., Lanza, Gregory M.·2006·Arteriosclerosis, Thrombosis, and Vascular Biology
DOI 10.1161/01.atv.0000235724.11299.76
Open this paper in CoChat — free account

Abstract

Objective— Angiogenic expansion of the vasa vasorum is a well-known feature of progressive atherosclerosis, suggesting that antiangiogenic therapies may stabilize or regress plaques. α ν β 3 Integrin–targeted paramagnetic nanoparticles were prepared for noninvasive assessment of angiogenesis in early atherosclerosis, for site-specific delivery of antiangiogenic drug, and for quantitative follow-up of response. Methods and Results— Expression of α ν β 3 integrin by vasa vasorum was imaged at 1.5 T in cholesterol-fed rabbit aortas using integrin-targeted paramagnetic nanoparticles that incorporated fumagillin at 0 μg/kg or 30 μg/kg. Both formulations produced similar MRI signal enhancement (16.7%±1.1%) when integrated across all aortic slices from the renal arteries to the diaphragm. Seven days after this single treatment, integrin-targeted paramagnetic nanoparticles were readministered and showed decreased MRI enhancement among fumagillin-treated rabbits (2.9%±1.6%) but not in untreated rabbits (18.1%±2.1%). In a third group of rabbits, nontargeted fumagillin nanoparticles did not alter vascular α ν β 3 -integrin expression (12.4%±0.9%; P >0.05) versus the no-drug control. In a second study focused on microscopic changes, fewer microvessels in the fumagillin-treated rabbit aorta were counted compared with control rabbits. Conclusions— This study illustrates the potential of combined molecular imaging and drug delivery with targeted nanoparticles to noninvasively define atherosclerotic burden, to deliver effective targeted drug at a fraction of previous levels, and to quantify local response to treatment.

Overview

Integrity signals

Registry

Crossref · 10.1161/01.atv.0000235724.11299.76

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Research works printed but not linked: 6

  1. 2003, Cancer Res, 63, 5838
  2. 10.1161/circ.105.4.415 · DOI
  3. 10.1161/circ.99.13.1726 · DOI
  4. 10.1172/JCI200420352 · DOI
  5. 10.1161/circ.104.11.1280 · DOI
  6. 1994, Am J Pathol, 145, 883

Cited by

Sorted by citations

Items 201–300 of 378

Related

See all

Metadata

Authors
Winter, P. M., Neubauer, A. M., Caruthers, S. D., Harris, T. D., Robertson, J. D., Williams, T. A., Schmieder, A. H., Hu, G., Allen, J. S., Lacy, E. K., Zhang, H., Wickline, S. A., & Lanza, G. M.
Affiliations
Washington University in St. Louis (US)
ORCID
Venue
Arteriosclerosis, Thrombosis, and Vascular Biology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2006-09
Volume
26
Issue
9
Pages
2103-2109
ISSN
  • 1079-5642 (ISSN-L)
  • 1524-4636
DOI
10.1161/01.atv.0000235724.11299.76
OpenAlex
W2112285684
Cited by
379
References
31
Citations by year
2026: 3 · 2025: 3 · 2024: 5 · 2023: 7 · 2022: 15 · 2021: 16 · 2020: 13 · 2019: 17 · 2018: 14 · 2017: 23 · 2016: 12 · 2015: 22 · 2014: 29 · 2013: 17 · 2012: 37
FWCI
13.04
Type
journal article
Language
en
Open access
closed
Locations
  • Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Heart, Lung, and Blood Institute (R01HL073646, HL-73646, R01HL078631, HL 78631)
  • National Cancer Institute (N01 CO 37007)
  • National Institute of Biomedical Imaging and Bioengineering (R01EB001704, EB-01704)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
Keywords
alpha v beta 3 integrin, fumagillin, targeted nanoparticles, angiogenesis inhibition, atherosclerosis, vasa vasorum, paramagnetic nanoparticles, magnetic resonance imaging, molecular imaging, targeted drug delivery, atherosclerotic plaque, rabbit aorta
MeSH terms
Animals, Aorta, Abdominal, Cyclohexanes, Endothelium, Vascular, Fatty Acids, Unsaturated, Hyperlipidemias, Magnetic Resonance Imaging, Neovascularization, Pathologic, Rabbits, Sesquiterpenes, Drug Delivery Systems, Angiogenesis Inhibitors, Integrin alphaVbeta3, Nanostructures, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review